Kent F Hoskins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1778657/publications.pdf

Version: 2024-02-01

		586496	620720
52	713	16	26
papers	citations	h-index	g-index
52	52	52	1314
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. Breast Cancer, 2022, 29, 287-295.	1.3	4
2	Abstract P3-14-11: Mammaprint and Blueprint identify genomic differences in HR+ HER2- breast cancers from young Black and White women. Cancer Research, 2022, 82, P3-14-11-P3-14-11.	0.4	O
3	Abstract P3-14-02: Racial/ethnic differences in the benefit of adjuvant chemotherapy for breast cancer patients with an intermediate risk 21-gene recurrence score. Cancer Research, 2022, 82, P3-14-02-P3-14-02.	0.4	O
4	Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer. Cancer Causes and Control, 2022, , 1.	0.8	0
5	Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 704-706.	1.1	O
6	Physical functioning, frailty and risks of locally-advanced breast cancer among older women. Breast, 2022, 64, 19-28.	0.9	0
7	Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity. Breast Cancer Research and Treatment, 2022, 193, 707-716.	1.1	11
8	Healthcare Predictors of Information Dissemination About Genetic Risks. Cancer Control, 2022, 29, 107327482211046.	0.7	1
9	Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk. BMC Health Services Research, 2022, 22, .	0.9	1
10	Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer–Specific Mortality Among US Women. JAMA Oncology, 2021, 7, 370.	3.4	64
11	Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer. Cancer, 2021, 127, 2535-2544.	2.0	15
12	Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen Journal of Clinical Oncology, 2021, 39, 1030-1030.	0.8	0
13	Disparities within luminal breast cancer: Clinical and molecular features of African American and non-Hispanic white patients Journal of Clinical Oncology, 2021, 39, 1009-1009.	0.8	4
14	Multi-gene prognostic assays and age-related differences in prediction of pathologic complete response to neoadjuvant chemotherapy and survival in breast cancer Journal of Clinical Oncology, 2021, 39, 591-591.	0.8	0
15	What accounts for the racial disparity in survival from estrogen receptor-positive, axillary node-negative breast cancer in the United States? An analysis of the SEER-Oncotype database Journal of Clinical Oncology, 2021, 39, 6534-6534.	0.8	O
16	Molecular characterization of luminal breast tumors in African American women Journal of Clinical Oncology, 2021, 39, 550-550.	0.8	2
17	A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer Journal of Clinical Oncology, 2021, 39, 1056-1056.	0.8	O
18	Associations between frailty and cancer-specific mortality among older women with breast cancer. Breast Cancer Research and Treatment, 2021, 189, 769-779.	1.1	10

#	Article	IF	CITATIONS
19	Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?. Cancer, 2021, , .	2.0	1
20	Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non–Safety-Net Centers. JCO Oncology Practice, 2021, 17, e1202-e1214.	1.4	2
21	Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancerâ€"Reply. JAMA Oncology, 2021, 7, 1248.	3.4	1
22	Association of Population Screening for Breast Cancer Risk With Use of Mammography Among Women in Medically Underserved Racial and Ethnic Minority Groups. JAMA Network Open, 2021, 4, e2123751.	2.8	16
23	Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. Breast, 2021, 59, 367-375.	0.9	3
24	Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8 ⁺ T cells., 2020, 8, e000494.		9
25	If you don't measure it, you can't improve it: Success and shortcomings of genomic assays in early breast cancer. Cancer, 2020, 126, 3922-3925.	2.0	0
26	Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7961-7970.	3.3	13
27	4R program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited?. Journal of Clinical Oncology, 2020, 38, 139-139.	0.8	1
28	Mammography adherence among medically underserved women undergoing cancer genetic risk assessment Journal of Clinical Oncology, 2020, 38, 1554-1554.	0.8	0
29	Promoting genetic counseling among African American women with hereditary risk for breast cancer Journal of Clinical Oncology, 2020, 38, e13639-e13639.	0.8	0
30	4R Care Delivery Program results: Impact of implementation metrics on patient self-management and 4R usefulness Journal of Clinical Oncology, 2020, 38, e14039-e14039.	0.8	0
31	4R Program results in breast cancer: the impact of 4R Care Delivery Model on timing and sequence of guideline recommended care Journal of Clinical Oncology, 2020, 38, 573-573.	0.8	0
32	4R Program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited?. Journal of Clinical Oncology, 2020, 38, e19211-e19211.	0.8	0
33	4R program results in breast cancer: The impact of 4R Care Delivery Model on timing and sequence of guideline recommended care Journal of Clinical Oncology, 2020, 38, 15-15.	0.8	42
34	4R Care Delivery Program results: Impact of implementation metrics on patient self-management and 4R usefulness Journal of Clinical Oncology, 2020, 38, 225-225.	0.8	1
35	Genetic Counseling and Testing in a Community Setting: Quality, Access, and Efficiency. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e34-e44.	1.8	56
36	Potassium channel activity controls breast cancer metastasis by affecting \hat{l}^2 -catenin signaling. Cell Death and Disease, 2019, 10, 180.	2.7	51

#	Article	IF	Citations
37	A feasibility study of breast cancer genetic risk assessment in a federally qualified health center. Cancer, 2018, 124, 3733-3741.	2.0	17
38	Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Research and Treatment, 2017, 163, 321-330.	1.1	34
39	Impact of a False-Positive Screening Mammogram on Subsequent Screening Behavior and Stage at Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 397-403.	1.1	27
40	Measures of economic advantage associated with HPV-positive head and neck cancers among non-Hispanic black and white males identified through the National Cancer Database. Cancer Epidemiology, 2017, 48, 1-7.	0.8	16
41	Selenium levels in human breast carcinoma tissue are associated with a common polymorphism in the gene for SELENOP (Selenoprotein P). Journal of Trace Elements in Medicine and Biology, 2017, 39, 227-233.	1.5	19
42	Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer $\hat{a} \in \text{``a SEER analysis. BMC Cancer, 2017, 17, 659.}$	1.1	8
43	Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer. Journal of Oncology Practice, 2017, 13, e451-e462.	2.5	37
44	Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors. Journal of Clinical Oncology, 2017, 35, 2820-2828.	0.8	41
45	Multi-gene hereditary cancer testing among men with breast cancer Journal of Clinical Oncology, 2017, 35, 1532-1532.	0.8	0
46	Family history of breast cancer in non- <i>BRCA</i> male breast cancer: A case-control study Journal of Clinical Oncology, 2017, 35, e13032-e13032.	0.8	0
47	Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study. Journal of Oncology Practice, 2015, 11, e460-e467.	2.5	18
48	The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: a population-based analysis of Cook County, Illinois. Annals of Epidemiology, 2015, 25, 556-563.	0.9	38
49	Racial and Ethnic Disparity in Symptomatic Breast Cancer Awareness despite a Recent Screen: The Role of Tumor Biology and Mammography Facility Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1599-1606.	1.1	21
50	Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes and Control, 2015, 26, 1065-1077.	0.8	31
51	The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago. Gynecologic Oncology, 2014, 135, 285-291.	0.6	18
52	Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer, 2006, 107, 1769-1776.	2.0	80